Cardiff Oncology to Host Webcast and Conference Call to Provide a Clinical and Corporate Update on September 12, 2022
Cardiff Oncology, Inc. (Nasdaq: CRDF) will host a webcast and conference call on September 12, 2022, at 4:30 PM ET, to discuss the development pathway for onvansertib in KRAS-mutated metastatic colorectal cancer, alongside updates on other programs. The event will include ongoing clinical trial data updates. In addition, Cardiff management will attend the Baird Global Healthcare Conference on September 13 and the H.C. Wainwright Global Investment Conference on September 14. Details of the call can be found on their website.
- None.
- None.
Event to feature discussions on the planned development pathway for onvansertib in KRAS-mutated metastatic colorectal cancer and updates on other development programs
Event to take place at 4:30 PM ET on Monday, September 12, 2022
SAN DIEGO, Aug. 29, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it will host a webcast and conference call to provide a clinical and corporate update on Monday, September 12, 2022. The event will feature discussions on the planned development pathway for onvansertib in KRAS-mutated metastatic colorectal cancer and updates on other development programs. In addition, company management will provide data updates from ongoing clinical trials.
Details on the conference call and webcast can be found below.
Date: | September 12, 2022 |
Time: | 4:30 PM ET |
Webcast Link: | |
U.S. Dial-in: | 1-877-407-9208 |
International Dial-in: | 1-201-493-6784 |
Conference ID: | 13731618 |
A replay of the webcast will be available by visiting the "Events" section of the Cardiff Oncology website after its conclusion.
Cardiff Oncology management will also participate in two upcoming investor conferences in New York.
- The Baird Global Healthcare Conference on September 13th
- The H.C. Wainwright 24th Annual Global Investment Conference on September 14th.
Conference details will be made available in the coming weeks.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor we are evaluating in combination with standard-of-care (SOC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SOC. For more information, please visit https://www.cardiffoncology.com.
Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Amy Jobe, Ph.D.
LifeSci Communications
315-879-8192
ajobe@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-to-host-webcast-and-conference-call-to-provide-a-clinical-and-corporate-update-on-september-12-2022-301613576.html
SOURCE Cardiff Oncology, Inc.
FAQ
What will Cardiff Oncology discuss in the September 12, 2022 call?
When is the Cardiff Oncology webcast scheduled?
How can I access the Cardiff Oncology conference call?
What investor conferences will Cardiff Oncology participate in September 2022?
What is Cardiff Oncology's stock symbol?
